Dasatinib treatment is well tolerated in patients with adenoid cystic carcinoma (ACC), a subtype of malignant salivary gland tumors, and resulted in tumor stabilization in 50% of patients, a new study published online ahead of print in the journal Annals of Oncology has shown.1
Because 90% of ACC cases express cKIT and dasatinib is a potent and selective inhibitor of cKIT, researchers sought to conduct a phase 2 study to evaluate the antitumor activity of the tyrosine kinase inhibitor in ACC and non-ACC malignant salivary gland tumors.
For the study, researchers enrolled 40 patients with progressive, recurrent/metastatic ACC and 14 with non-ACC. All participants received dasatinib 70 mg orally twice daily.
Efficacy results showed that 1 patient with ACC achieved a partial response and 20 had stable disease. Twelve had progressive disease. Researchers found that median progression-free survival and median overall survival was 4.8 months and 14.5 months, respectively. No patients with non-ACC achieved an objective response, 7 had stable disease, and 4 had progressive disease.
RELATED: Head and Neck Cancer Patients Have Higher Suicide Risk
In regard to safety, the most frequent grade 2 or higher adverse events were fatigue, nausea, lymphopenia, dyspnea, increased alanine aminotransferase, anorexia, vomiting, increased alkaline phosphatase, diarrhea, neutropenia, and non-cardiac chest pain. No patients experienced a grade 4 adverse event.
The findings suggest that dasatinib is not active in non-ACC malignant salivary gland tumors, but may have some activity in patients with ACC.
- Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for non-adenoid cystic malignant salivary tumors [published online ahead of print on November 23, 2015]. Ann Oncol. doi: 10.1093/annonc/mdv537.